eli lilly glp-1 winner vs Novo Nordisk vs Pfizer: Who's Winning? Eli Lilly: No Big Gap
Description
adults will have obesity by 2035a burden that doesn't affect all races and ethnicities equally
Preclinical and observational data suggested possible benefits, spurring rigorous clinical testing
Early reports suggested a possible increase in thyroid tumors
Both are provider led and ship monthly
Tirzepatide, the first dual GIP/GLP-1 receptor co-agonist approved for type 2 diabetes in the USA, Europe, and the UAE, targets both appetite and glucose control
